TABLE 3.
HPV11 L1 interactions with L2 proteins from other papillomaviruses
| Virus | Host | Location of infection (level of risk)a | Supergroupb | L1/L2 ratioc | Interaction with HPV11 L1d |
|---|---|---|---|---|---|
| HPV11 | Human | Genital tract (low) | A10 | >1:1 | Strong |
| HPV6b | Human | Genital tract (low) | A10 | >1:1 | Strong |
| HPV16 | Human | Genital tract (high) | A9 | >1:1 | Strong |
| HPV33 | Human | Genital tract (moderate) | A9 | >1:1 | Strong |
| HPV1a | Human | Skin | E1 | ND | Undetectable |
| HPV5 | Human | Skin | B1 | <1:1 | Weak |
| HPV12 | Human | Skin | B1 | <1:1 | Weak |
| COPV1 | Dog | Oral | E | <1:1 | Weak |
| BPV1 | Cow | Skin | C1 | ND | Undetectable |
a
Risk of genital tract isolates for progression to cervical carcinoma.
b
Supergroup designation is that defined in Human Papillomaviruses (1) based on a phylogenetic tree computed from a consensus primer region of L1.
c
Relative amounts of L1 to the GST=L2 fusion proteins indicated with aterisks on Fig. 6A were determined by densitometric analysis of Coomassie blue-stained SDS-polyacrylamide gels.
d
Strength of interaction with L1 is based on the ability to detect L1 by immunoblot analysis, as well as the relative amounts of L1 and L2. ND, not determined.